nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—SLC31A1—Carboplatin—breast cancer	0.0877	0.254	CbGbCtD
Bortezomib—PTGS1—breast cancer	0.0848	0.315	CbGaD
Bortezomib—CYP1A1—breast cancer	0.0776	0.288	CbGaD
Bortezomib—CYP2D6—breast cancer	0.0577	0.214	CbGaD
Bortezomib—CYP3A4—breast cancer	0.0495	0.184	CbGaD
Bortezomib—CYP1A1—Toremifene—breast cancer	0.0287	0.083	CbGbCtD
Bortezomib—CYP1A2—Anastrozole—breast cancer	0.014	0.0405	CbGbCtD
Bortezomib—CYP1A2—Toremifene—breast cancer	0.0128	0.0371	CbGbCtD
Bortezomib—CYP2C9—Anastrozole—breast cancer	0.0126	0.0365	CbGbCtD
Bortezomib—CYP2C8—Lapatinib—breast cancer	0.0121	0.0349	CbGbCtD
Bortezomib—CYP1A1—Tamoxifen—breast cancer	0.0105	0.0303	CbGbCtD
Bortezomib—CYP2C19—Lapatinib—breast cancer	0.0101	0.0293	CbGbCtD
Bortezomib—CYP3A4—Exemestane—breast cancer	0.00969	0.028	CbGbCtD
Bortezomib—CYP2C9—Idarubicin—breast cancer	0.00957	0.0277	CbGbCtD
Bortezomib—CYP2C8—Raloxifene—breast cancer	0.00916	0.0265	CbGbCtD
Bortezomib—CYP2D6—Idarubicin—breast cancer	0.00876	0.0253	CbGbCtD
Bortezomib—CYP3A4—Letrozole—breast cancer	0.00824	0.0238	CbGbCtD
Bortezomib—CYP3A4—Anastrozole—breast cancer	0.00735	0.0212	CbGbCtD
Bortezomib—CYP3A4—Toremifene—breast cancer	0.00672	0.0194	CbGbCtD
Bortezomib—CYP3A4—Fulvestrant—breast cancer	0.00625	0.0181	CbGbCtD
Bortezomib—CYP2C8—Tamoxifen—breast cancer	0.00605	0.0175	CbGbCtD
Bortezomib—CYP3A4—Thiotepa—breast cancer	0.00557	0.0161	CbGbCtD
Bortezomib—CYP2C9—Capecitabine—breast cancer	0.00525	0.0152	CbGbCtD
Bortezomib—CYP3A4—Ixabepilone—breast cancer	0.00509	0.0147	CbGbCtD
Bortezomib—CYP2C19—Tamoxifen—breast cancer	0.00508	0.0147	CbGbCtD
Bortezomib—CYP3A4—Lapatinib—breast cancer	0.0049	0.0142	CbGbCtD
Bortezomib—CYP2C8—Paclitaxel—breast cancer	0.00471	0.0136	CbGbCtD
Bortezomib—CYP1A2—Tamoxifen—breast cancer	0.00468	0.0135	CbGbCtD
Bortezomib—CYP2C8—Fluorouracil—breast cancer	0.00446	0.0129	CbGbCtD
Bortezomib—CYP2D6—Vinorelbine—breast cancer	0.00428	0.0124	CbGbCtD
Bortezomib—CYP2C9—Tamoxifen—breast cancer	0.00422	0.0122	CbGbCtD
Bortezomib—CYP2D6—Tamoxifen—breast cancer	0.00386	0.0112	CbGbCtD
Bortezomib—CYP3A4—Raloxifene—breast cancer	0.00371	0.0107	CbGbCtD
Bortezomib—CYP1A2—Fluorouracil—breast cancer	0.00345	0.00998	CbGbCtD
Bortezomib—CYP2C9—Paclitaxel—breast cancer	0.00329	0.0095	CbGbCtD
Bortezomib—CYP2C9—Fluorouracil—breast cancer	0.00311	0.00899	CbGbCtD
Bortezomib—CYP3A4—Vinorelbine—breast cancer	0.00272	0.00786	CbGbCtD
Bortezomib—CYP2D6—Vinblastine—breast cancer	0.00263	0.00762	CbGbCtD
Bortezomib—CYP3A4—Tamoxifen—breast cancer	0.00245	0.0071	CbGbCtD
Bortezomib—CYP3A4—Mitoxantrone—breast cancer	0.00239	0.00692	CbGbCtD
Bortezomib—CYP3A4—Paclitaxel—breast cancer	0.00191	0.00552	CbGbCtD
Bortezomib—CYP3A4—Irinotecan—breast cancer	0.00188	0.00545	CbGbCtD
Bortezomib—CTSG—nipple—breast cancer	0.00171	0.0244	CbGeAlD
Bortezomib—CYP3A4—Vinblastine—breast cancer	0.00168	0.00485	CbGbCtD
Bortezomib—PSMD1—mammary gland—breast cancer	0.00166	0.0237	CbGeAlD
Bortezomib—CYP2D6—Doxorubicin—breast cancer	0.00162	0.00468	CbGbCtD
Bortezomib—PSMD2—mammary gland—breast cancer	0.00147	0.021	CbGeAlD
Bortezomib—CYP3A4—Docetaxel—breast cancer	0.00138	0.00399	CbGbCtD
Bortezomib—PSMD1—nipple—breast cancer	0.00138	0.0196	CbGeAlD
Bortezomib—PSMA1—embryo—breast cancer	0.00135	0.0193	CbGeAlD
Bortezomib—PSMD2—nipple—breast cancer	0.00122	0.0174	CbGeAlD
Bortezomib—PSMB8—nipple—breast cancer	0.00121	0.0173	CbGeAlD
Bortezomib—PSMA1—epithelium—breast cancer	0.0011	0.0157	CbGeAlD
Bortezomib—PSMB2—mammary gland—breast cancer	0.0011	0.0157	CbGeAlD
Bortezomib—CTSG—skin of body—breast cancer	0.00109	0.0156	CbGeAlD
Bortezomib—PSMB5—nipple—breast cancer	0.00107	0.0153	CbGeAlD
Bortezomib—PSMA1—skin of body—breast cancer	0.00105	0.015	CbGeAlD
Bortezomib—CYP3A4—Doxorubicin—breast cancer	0.00103	0.00298	CbGbCtD
Bortezomib—PSMD2—embryo—breast cancer	0.00101	0.0143	CbGeAlD
Bortezomib—PSMB1—nipple—breast cancer	0.000935	0.0133	CbGeAlD
Bortezomib—CTSG—adipose tissue—breast cancer	0.000929	0.0133	CbGeAlD
Bortezomib—PSMB2—nipple—breast cancer	0.000912	0.013	CbGeAlD
Bortezomib—PSMA1—uterus—breast cancer	0.000912	0.013	CbGeAlD
Bortezomib—PSMA1—adipose tissue—breast cancer	0.000892	0.0127	CbGeAlD
Bortezomib—CTSG—adrenal gland—breast cancer	0.000833	0.0119	CbGeAlD
Bortezomib—PSMD1—endometrium—breast cancer	0.00083	0.0119	CbGeAlD
Bortezomib—PSMA1—female reproductive system—breast cancer	0.000819	0.0117	CbGeAlD
Bortezomib—CTSG—bone marrow—breast cancer	0.000806	0.0115	CbGeAlD
Bortezomib—PSMA1—adrenal gland—breast cancer	0.0008	0.0114	CbGeAlD
Bortezomib—SLC31A1—nipple—breast cancer	0.00079	0.0113	CbGeAlD
Bortezomib—PSMD2—skin of body—breast cancer	0.00078	0.0111	CbGeAlD
Bortezomib—PSMA1—bone marrow—breast cancer	0.000774	0.011	CbGeAlD
Bortezomib—PSMB1—embryo—breast cancer	0.000771	0.011	CbGeAlD
Bortezomib—PSMD1—uterus—breast cancer	0.000765	0.0109	CbGeAlD
Bortezomib—PSMB2—embryo—breast cancer	0.000753	0.0107	CbGeAlD
Bortezomib—PSMD1—pituitary gland—breast cancer	0.000752	0.0107	CbGeAlD
Bortezomib—PSMD1—adipose tissue—breast cancer	0.000748	0.0107	CbGeAlD
Bortezomib—PSMA1—female gonad—breast cancer	0.000746	0.0106	CbGeAlD
Bortezomib—PSMD2—endometrium—breast cancer	0.000736	0.0105	CbGeAlD
Bortezomib—PSMB8—endometrium—breast cancer	0.000731	0.0104	CbGeAlD
Bortezomib—CTSG—endocrine gland—breast cancer	0.000722	0.0103	CbGeAlD
Bortezomib—PSMA1—endocrine gland—breast cancer	0.000693	0.0099	CbGeAlD
Bortezomib—PSMD2—uterus—breast cancer	0.000678	0.00967	CbGeAlD
Bortezomib—PSMD1—adrenal gland—breast cancer	0.000671	0.00958	CbGeAlD
Bortezomib—PSMD2—pituitary gland—breast cancer	0.000666	0.0095	CbGeAlD
Bortezomib—PSMD2—adipose tissue—breast cancer	0.000663	0.00946	CbGeAlD
Bortezomib—PSMB8—pituitary gland—breast cancer	0.000662	0.00944	CbGeAlD
Bortezomib—PSMB8—adipose tissue—breast cancer	0.000659	0.0094	CbGeAlD
Bortezomib—PSMD1—bone marrow—breast cancer	0.000649	0.00927	CbGeAlD
Bortezomib—PSMB5—endometrium—breast cancer	0.000646	0.00922	CbGeAlD
Bortezomib—PSMD1—female gonad—breast cancer	0.000626	0.00893	CbGeAlD
Bortezomib—PSMD2—female reproductive system—breast cancer	0.000609	0.0087	CbGeAlD
Bortezomib—PSMB1—skin of body—breast cancer	0.000599	0.00854	CbGeAlD
Bortezomib—PSMB5—uterus—breast cancer	0.000595	0.00849	CbGeAlD
Bortezomib—PSMD2—adrenal gland—breast cancer	0.000595	0.00849	CbGeAlD
Bortezomib—PSMB8—adrenal gland—breast cancer	0.000591	0.00844	CbGeAlD
Bortezomib—PSMB5—pituitary gland—breast cancer	0.000584	0.00834	CbGeAlD
Bortezomib—PSMB2—skin of body—breast cancer	0.000584	0.00834	CbGeAlD
Bortezomib—PSMB5—adipose tissue—breast cancer	0.000582	0.00831	CbGeAlD
Bortezomib—PSMD2—bone marrow—breast cancer	0.000575	0.00821	CbGeAlD
Bortezomib—PSMB8—bone marrow—breast cancer	0.000572	0.00816	CbGeAlD
Bortezomib—PSMB1—endometrium—breast cancer	0.000565	0.00806	CbGeAlD
Bortezomib—PSMD2—female gonad—breast cancer	0.000555	0.00791	CbGeAlD
Bortezomib—PSMB8—female gonad—breast cancer	0.000551	0.00787	CbGeAlD
Bortezomib—PSMB2—endometrium—breast cancer	0.000551	0.00786	CbGeAlD
Bortezomib—PSMB5—adrenal gland—breast cancer	0.000522	0.00745	CbGeAlD
Bortezomib—PSMB1—uterus—breast cancer	0.00052	0.00742	CbGeAlD
Bortezomib—PSMD2—endocrine gland—breast cancer	0.000516	0.00736	CbGeAlD
Bortezomib—PSMB1—pituitary gland—breast cancer	0.000511	0.00729	CbGeAlD
Bortezomib—PSMB1—adipose tissue—breast cancer	0.000509	0.00726	CbGeAlD
Bortezomib—PSMB2—uterus—breast cancer	0.000508	0.00724	CbGeAlD
Bortezomib—PSMB5—bone marrow—breast cancer	0.000505	0.00721	CbGeAlD
Bortezomib—CTSG—lymph node—breast cancer	0.000499	0.00713	CbGeAlD
Bortezomib—PSMB2—pituitary gland—breast cancer	0.000498	0.00711	CbGeAlD
Bortezomib—PSMB2—adipose tissue—breast cancer	0.000496	0.00708	CbGeAlD
Bortezomib—PSMB5—female gonad—breast cancer	0.000487	0.00695	CbGeAlD
Bortezomib—PSMA1—lymph node—breast cancer	0.000479	0.00684	CbGeAlD
Bortezomib—SLC31A1—endometrium—breast cancer	0.000477	0.00681	CbGeAlD
Bortezomib—Lacosamide—SCN10A—breast cancer	0.000474	0.337	CrCbGaD
Bortezomib—PSMB1—female reproductive system—breast cancer	0.000468	0.00667	CbGeAlD
Bortezomib—PSMB1—adrenal gland—breast cancer	0.000456	0.00651	CbGeAlD
Bortezomib—PSMB2—female reproductive system—breast cancer	0.000456	0.00651	CbGeAlD
Bortezomib—PSMB2—adrenal gland—breast cancer	0.000445	0.00635	CbGeAlD
Bortezomib—PSMB1—bone marrow—breast cancer	0.000441	0.0063	CbGeAlD
Bortezomib—Lacosamide—CA9—breast cancer	0.000434	0.308	CrCbGaD
Bortezomib—SLC31A1—pituitary gland—breast cancer	0.000432	0.00616	CbGeAlD
Bortezomib—PSMB2—bone marrow—breast cancer	0.000431	0.00615	CbGeAlD
Bortezomib—SLC31A1—adipose tissue—breast cancer	0.00043	0.00613	CbGeAlD
Bortezomib—PSMB1—female gonad—breast cancer	0.000426	0.00607	CbGeAlD
Bortezomib—PSMB2—female gonad—breast cancer	0.000415	0.00592	CbGeAlD
Bortezomib—PSMD1—lymph node—breast cancer	0.000402	0.00574	CbGeAlD
Bortezomib—PSMB1—endocrine gland—breast cancer	0.000396	0.00565	CbGeAlD
Bortezomib—SLC31A1—female reproductive system—breast cancer	0.000395	0.00564	CbGeAlD
Bortezomib—PSMB2—endocrine gland—breast cancer	0.000386	0.00551	CbGeAlD
Bortezomib—SLC31A1—adrenal gland—breast cancer	0.000386	0.0055	CbGeAlD
Bortezomib—SLC31A1—bone marrow—breast cancer	0.000373	0.00532	CbGeAlD
Bortezomib—SLC31A1—female gonad—breast cancer	0.00036	0.00513	CbGeAlD
Bortezomib—PSMD2—lymph node—breast cancer	0.000356	0.00509	CbGeAlD
Bortezomib—PSMB8—lymph node—breast cancer	0.000354	0.00506	CbGeAlD
Bortezomib—CYP2C8—mammary gland—breast cancer	0.000351	0.00502	CbGeAlD
Bortezomib—SLC31A1—endocrine gland—breast cancer	0.000334	0.00477	CbGeAlD
Bortezomib—PSMB2—Azacitidine—Gemcitabine—breast cancer	0.000332	0.145	CbGdCrCtD
Bortezomib—PSMB8—Vincristine—Vinorelbine—breast cancer	0.000316	0.138	CbGdCrCtD
Bortezomib—PSMB5—lymph node—breast cancer	0.000313	0.00447	CbGeAlD
Bortezomib—CYP2C9—mammary gland—breast cancer	0.000312	0.00445	CbGeAlD
Bortezomib—PSMB8—Vinorelbine—Vinblastine—breast cancer	0.000295	0.129	CbGdCrCtD
Bortezomib—PSMB1—lymph node—breast cancer	0.000274	0.0039	CbGeAlD
Bortezomib—CYP1A2—nipple—breast cancer	0.000272	0.00388	CbGeAlD
Bortezomib—CYP1A1—nipple—breast cancer	0.000268	0.00383	CbGeAlD
Bortezomib—PSMB2—lymph node—breast cancer	0.000267	0.00381	CbGeAlD
Bortezomib—PSMB8—Vincristine—Vinblastine—breast cancer	0.000252	0.11	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Fluoxymesterone—breast cancer	0.00024	0.105	CbGdCrCtD
Bortezomib—PTGS1—nipple—breast cancer	0.000236	0.00336	CbGeAlD
Bortezomib—SLC31A1—lymph node—breast cancer	0.000231	0.0033	CbGeAlD
Bortezomib—PSMB8—Testosterone Propionate—Fluoxymesterone—breast cancer	0.000185	0.0806	CbGdCrCtD
Bortezomib—CYP1A1—epithelium—breast cancer	0.000181	0.00258	CbGeAlD
Bortezomib—Nateglinide—PTGS1—breast cancer	0.00018	0.128	CrCbGaD
Bortezomib—CYP2C8—endometrium—breast cancer	0.000176	0.0025	CbGeAlD
Bortezomib—CYP1A1—skin of body—breast cancer	0.000172	0.00245	CbGeAlD
Bortezomib—PSMD2—Dexamethasone—Fluoxymesterone—breast cancer	0.000169	0.0737	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Fluoxymesterone—breast cancer	0.000169	0.0737	CbGdCrCtD
Bortezomib—CYP2C8—pituitary gland—breast cancer	0.000159	0.00227	CbGeAlD
Bortezomib—PTGS1—epithelium—breast cancer	0.000159	0.00226	CbGeAlD
Bortezomib—PTGS1—skin of body—breast cancer	0.000151	0.00215	CbGeAlD
Bortezomib—CYP1A1—uterus—breast cancer	0.000149	0.00213	CbGeAlD
Bortezomib—CYP1A1—adipose tissue—breast cancer	0.000146	0.00208	CbGeAlD
Bortezomib—CYP2C8—female reproductive system—breast cancer	0.000145	0.00207	CbGeAlD
Bortezomib—PTGS1—endometrium—breast cancer	0.000142	0.00203	CbGeAlD
Bortezomib—CYP2C19—endocrine gland—breast cancer	0.000141	0.00201	CbGeAlD
Bortezomib—PSMB8—Norethindrone—Fluoxymesterone—breast cancer	0.000138	0.0604	CbGdCrCtD
Bortezomib—CYP1A1—female reproductive system—breast cancer	0.000134	0.00192	CbGeAlD
Bortezomib—PTGS1—uterus—breast cancer	0.000131	0.00187	CbGeAlD
Bortezomib—CYP2C9—female reproductive system—breast cancer	0.000129	0.00184	CbGeAlD
Bortezomib—PTGS1—pituitary gland—breast cancer	0.000129	0.00184	CbGeAlD
Bortezomib—PTGS1—adipose tissue—breast cancer	0.000128	0.00183	CbGeAlD
Bortezomib—CYP2C8—endocrine gland—breast cancer	0.000123	0.00176	CbGeAlD
Bortezomib—Nateglinide—CYP2D6—breast cancer	0.000123	0.0872	CrCbGaD
Bortezomib—CYP1A1—female gonad—breast cancer	0.000122	0.00174	CbGeAlD
Bortezomib—PTGS1—female reproductive system—breast cancer	0.000118	0.00168	CbGeAlD
Bortezomib—CYP1A2—endocrine gland—breast cancer	0.000115	0.00164	CbGeAlD
Bortezomib—PTGS1—adrenal gland—breast cancer	0.000115	0.00164	CbGeAlD
Bortezomib—CYP1A1—endocrine gland—breast cancer	0.000114	0.00162	CbGeAlD
Bortezomib—CYP2C9—endocrine gland—breast cancer	0.000109	0.00156	CbGeAlD
Bortezomib—PTGS1—female gonad—breast cancer	0.000107	0.00153	CbGeAlD
Bortezomib—Nateglinide—CYP3A4—breast cancer	0.000105	0.0748	CrCbGaD
Bortezomib—PTGS1—endocrine gland—breast cancer	9.98e-05	0.00142	CbGeAlD
Bortezomib—CYP3A4—female reproductive system—breast cancer	9.85e-05	0.00141	CbGeAlD
Bortezomib—PSMB8—Dexamethasone—Fluoxymesterone—breast cancer	9.81e-05	0.0428	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Fluoxymesterone—breast cancer	9.81e-05	0.0428	CbGdCrCtD
Bortezomib—CYP2D6—female reproductive system—breast cancer	9.69e-05	0.00138	CbGeAlD
Bortezomib—Nateglinide—ALB—breast cancer	9.19e-05	0.0652	CrCbGaD
Bortezomib—CYP2D6—female gonad—breast cancer	8.82e-05	0.00126	CbGeAlD
Bortezomib—CYP3A4—endocrine gland—breast cancer	8.33e-05	0.00119	CbGeAlD
Bortezomib—CYP2D6—endocrine gland—breast cancer	8.2e-05	0.00117	CbGeAlD
Bortezomib—CYP1A1—lymph node—breast cancer	7.85e-05	0.00112	CbGeAlD
Bortezomib—PTGS1—lymph node—breast cancer	6.9e-05	0.000984	CbGeAlD
Bortezomib—Decreased appetite—Docetaxel—breast cancer	1.01e-05	5.67e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Paclitaxel—breast cancer	1.01e-05	5.67e-05	CcSEcCtD
Bortezomib—Headache—Fluorouracil—breast cancer	1.01e-05	5.66e-05	CcSEcCtD
Bortezomib—Urinary tract disorder—Doxorubicin—breast cancer	1.01e-05	5.66e-05	CcSEcCtD
Bortezomib—Oedema peripheral—Doxorubicin—breast cancer	1.01e-05	5.65e-05	CcSEcCtD
Bortezomib—Dysgeusia—Methotrexate—breast cancer	1e-05	5.64e-05	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Docetaxel—breast cancer	1e-05	5.63e-05	CcSEcCtD
Bortezomib—Connective tissue disorder—Doxorubicin—breast cancer	1e-05	5.63e-05	CcSEcCtD
Bortezomib—Dyspnoea—Capecitabine—breast cancer	1e-05	5.63e-05	CcSEcCtD
Bortezomib—Fatigue—Docetaxel—breast cancer	1e-05	5.62e-05	CcSEcCtD
Bortezomib—Angiopathy—Epirubicin—breast cancer	1e-05	5.62e-05	CcSEcCtD
Bortezomib—Urethral disorder—Doxorubicin—breast cancer	1e-05	5.62e-05	CcSEcCtD
Bortezomib—Nausea—Irinotecan—breast cancer	9.99e-06	5.61e-05	CcSEcCtD
Bortezomib—Nausea—Mitoxantrone—breast cancer	9.99e-06	5.61e-05	CcSEcCtD
Bortezomib—Immune system disorder—Epirubicin—breast cancer	9.97e-06	5.59e-05	CcSEcCtD
Bortezomib—Mediastinal disorder—Epirubicin—breast cancer	9.94e-06	5.58e-05	CcSEcCtD
Bortezomib—Pain—Docetaxel—breast cancer	9.94e-06	5.58e-05	CcSEcCtD
Bortezomib—Constipation—Docetaxel—breast cancer	9.94e-06	5.58e-05	CcSEcCtD
Bortezomib—Back pain—Methotrexate—breast cancer	9.93e-06	5.57e-05	CcSEcCtD
Bortezomib—Dyspepsia—Capecitabine—breast cancer	9.9e-06	5.56e-05	CcSEcCtD
Bortezomib—Chills—Epirubicin—breast cancer	9.9e-06	5.56e-05	CcSEcCtD
Bortezomib—Arrhythmia—Epirubicin—breast cancer	9.86e-06	5.53e-05	CcSEcCtD
Bortezomib—Visual impairment—Doxorubicin—breast cancer	9.84e-06	5.52e-05	CcSEcCtD
Bortezomib—Asthenia—Paclitaxel—breast cancer	9.84e-06	5.52e-05	CcSEcCtD
Bortezomib—Decreased appetite—Capecitabine—breast cancer	9.78e-06	5.49e-05	CcSEcCtD
Bortezomib—Nausea—Gemcitabine—breast cancer	9.73e-06	5.46e-05	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Capecitabine—breast cancer	9.71e-06	5.45e-05	CcSEcCtD
Bortezomib—Fatigue—Capecitabine—breast cancer	9.7e-06	5.45e-05	CcSEcCtD
Bortezomib—Pruritus—Paclitaxel—breast cancer	9.7e-06	5.44e-05	CcSEcCtD
Bortezomib—Vision blurred—Methotrexate—breast cancer	9.67e-06	5.43e-05	CcSEcCtD
Bortezomib—Mental disorder—Epirubicin—breast cancer	9.67e-06	5.43e-05	CcSEcCtD
Bortezomib—Erythema multiforme—Doxorubicin—breast cancer	9.65e-06	5.42e-05	CcSEcCtD
Bortezomib—Constipation—Capecitabine—breast cancer	9.62e-06	5.4e-05	CcSEcCtD
Bortezomib—Pain—Capecitabine—breast cancer	9.62e-06	5.4e-05	CcSEcCtD
Bortezomib—Erythema—Epirubicin—breast cancer	9.6e-06	5.39e-05	CcSEcCtD
Bortezomib—Malnutrition—Epirubicin—breast cancer	9.6e-06	5.39e-05	CcSEcCtD
Bortezomib—Feeling abnormal—Docetaxel—breast cancer	9.58e-06	5.38e-05	CcSEcCtD
Bortezomib—Nausea—Fluorouracil—breast cancer	9.56e-06	5.37e-05	CcSEcCtD
Bortezomib—Eye disorder—Doxorubicin—breast cancer	9.54e-06	5.36e-05	CcSEcCtD
Bortezomib—Ill-defined disorder—Methotrexate—breast cancer	9.52e-06	5.35e-05	CcSEcCtD
Bortezomib—Tinnitus—Doxorubicin—breast cancer	9.52e-06	5.34e-05	CcSEcCtD
Bortezomib—Gastrointestinal pain—Docetaxel—breast cancer	9.5e-06	5.33e-05	CcSEcCtD
Bortezomib—Anaemia—Methotrexate—breast cancer	9.49e-06	5.32e-05	CcSEcCtD
Bortezomib—Flushing—Doxorubicin—breast cancer	9.47e-06	5.32e-05	CcSEcCtD
Bortezomib—Cardiac disorder—Doxorubicin—breast cancer	9.47e-06	5.32e-05	CcSEcCtD
Bortezomib—Flatulence—Epirubicin—breast cancer	9.46e-06	5.31e-05	CcSEcCtD
Bortezomib—Dysgeusia—Epirubicin—breast cancer	9.41e-06	5.28e-05	CcSEcCtD
Bortezomib—Diarrhoea—Paclitaxel—breast cancer	9.38e-06	5.27e-05	CcSEcCtD
Bortezomib—Back pain—Epirubicin—breast cancer	9.29e-06	5.21e-05	CcSEcCtD
Bortezomib—Feeling abnormal—Capecitabine—breast cancer	9.27e-06	5.2e-05	CcSEcCtD
Bortezomib—Angiopathy—Doxorubicin—breast cancer	9.26e-06	5.2e-05	CcSEcCtD
Bortezomib—Malaise—Methotrexate—breast cancer	9.25e-06	5.2e-05	CcSEcCtD
Bortezomib—Muscle spasms—Epirubicin—breast cancer	9.23e-06	5.18e-05	CcSEcCtD
Bortezomib—Immune system disorder—Doxorubicin—breast cancer	9.22e-06	5.18e-05	CcSEcCtD
Bortezomib—Vertigo—Methotrexate—breast cancer	9.22e-06	5.18e-05	CcSEcCtD
Bortezomib—Gastrointestinal pain—Capecitabine—breast cancer	9.2e-06	5.16e-05	CcSEcCtD
Bortezomib—Mediastinal disorder—Doxorubicin—breast cancer	9.2e-06	5.16e-05	CcSEcCtD
Bortezomib—Abdominal pain—Docetaxel—breast cancer	9.19e-06	5.16e-05	CcSEcCtD
Bortezomib—Body temperature increased—Docetaxel—breast cancer	9.19e-06	5.16e-05	CcSEcCtD
Bortezomib—Leukopenia—Methotrexate—breast cancer	9.19e-06	5.16e-05	CcSEcCtD
Bortezomib—Chills—Doxorubicin—breast cancer	9.16e-06	5.14e-05	CcSEcCtD
Bortezomib—Arrhythmia—Doxorubicin—breast cancer	9.12e-06	5.12e-05	CcSEcCtD
Bortezomib—Dizziness—Paclitaxel—breast cancer	9.07e-06	5.09e-05	CcSEcCtD
Bortezomib—Vision blurred—Epirubicin—breast cancer	9.05e-06	5.08e-05	CcSEcCtD
Bortezomib—Cough—Methotrexate—breast cancer	8.96e-06	5.03e-05	CcSEcCtD
Bortezomib—Mental disorder—Doxorubicin—breast cancer	8.94e-06	5.02e-05	CcSEcCtD
Bortezomib—Urticaria—Capecitabine—breast cancer	8.94e-06	5.02e-05	CcSEcCtD
Bortezomib—Ill-defined disorder—Epirubicin—breast cancer	8.91e-06	5e-05	CcSEcCtD
Bortezomib—Abdominal pain—Capecitabine—breast cancer	8.89e-06	4.99e-05	CcSEcCtD
Bortezomib—Body temperature increased—Capecitabine—breast cancer	8.89e-06	4.99e-05	CcSEcCtD
Bortezomib—Convulsion—Methotrexate—breast cancer	8.89e-06	4.99e-05	CcSEcCtD
Bortezomib—Malnutrition—Doxorubicin—breast cancer	8.89e-06	4.99e-05	CcSEcCtD
Bortezomib—Erythema—Doxorubicin—breast cancer	8.89e-06	4.99e-05	CcSEcCtD
Bortezomib—Anaemia—Epirubicin—breast cancer	8.88e-06	4.98e-05	CcSEcCtD
Bortezomib—Agitation—Epirubicin—breast cancer	8.83e-06	4.95e-05	CcSEcCtD
Bortezomib—Flatulence—Doxorubicin—breast cancer	8.76e-06	4.92e-05	CcSEcCtD
Bortezomib—Chest pain—Methotrexate—breast cancer	8.74e-06	4.9e-05	CcSEcCtD
Bortezomib—Arthralgia—Methotrexate—breast cancer	8.74e-06	4.9e-05	CcSEcCtD
Bortezomib—Myalgia—Methotrexate—breast cancer	8.74e-06	4.9e-05	CcSEcCtD
Bortezomib—Vomiting—Paclitaxel—breast cancer	8.72e-06	4.89e-05	CcSEcCtD
Bortezomib—Dysgeusia—Doxorubicin—breast cancer	8.7e-06	4.88e-05	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	8.68e-06	4.87e-05	CcSEcCtD
Bortezomib—Malaise—Epirubicin—breast cancer	8.66e-06	4.86e-05	CcSEcCtD
Bortezomib—Rash—Paclitaxel—breast cancer	8.64e-06	4.85e-05	CcSEcCtD
Bortezomib—Dermatitis—Paclitaxel—breast cancer	8.64e-06	4.85e-05	CcSEcCtD
Bortezomib—Discomfort—Methotrexate—breast cancer	8.63e-06	4.85e-05	CcSEcCtD
Bortezomib—Vertigo—Epirubicin—breast cancer	8.63e-06	4.84e-05	CcSEcCtD
Bortezomib—Syncope—Epirubicin—breast cancer	8.61e-06	4.83e-05	CcSEcCtD
Bortezomib—Leukopenia—Epirubicin—breast cancer	8.6e-06	4.83e-05	CcSEcCtD
Bortezomib—Back pain—Doxorubicin—breast cancer	8.6e-06	4.83e-05	CcSEcCtD
Bortezomib—Headache—Paclitaxel—breast cancer	8.59e-06	4.82e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Docetaxel—breast cancer	8.56e-06	4.81e-05	CcSEcCtD
Bortezomib—Muscle spasms—Doxorubicin—breast cancer	8.54e-06	4.8e-05	CcSEcCtD
Bortezomib—Palpitations—Epirubicin—breast cancer	8.49e-06	4.76e-05	CcSEcCtD
Bortezomib—Confusional state—Methotrexate—breast cancer	8.45e-06	4.74e-05	CcSEcCtD
Bortezomib—Loss of consciousness—Epirubicin—breast cancer	8.44e-06	4.74e-05	CcSEcCtD
Bortezomib—Cough—Epirubicin—breast cancer	8.38e-06	4.7e-05	CcSEcCtD
Bortezomib—Anaphylactic shock—Methotrexate—breast cancer	8.38e-06	4.7e-05	CcSEcCtD
Bortezomib—Vision blurred—Doxorubicin—breast cancer	8.37e-06	4.7e-05	CcSEcCtD
Bortezomib—Asthenia—Docetaxel—breast cancer	8.34e-06	4.68e-05	CcSEcCtD
Bortezomib—Convulsion—Epirubicin—breast cancer	8.32e-06	4.67e-05	CcSEcCtD
Bortezomib—Infection—Methotrexate—breast cancer	8.32e-06	4.67e-05	CcSEcCtD
Bortezomib—Hypertension—Epirubicin—breast cancer	8.29e-06	4.65e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Capecitabine—breast cancer	8.29e-06	4.65e-05	CcSEcCtD
Bortezomib—Ill-defined disorder—Doxorubicin—breast cancer	8.25e-06	4.63e-05	CcSEcCtD
Bortezomib—Pruritus—Docetaxel—breast cancer	8.22e-06	4.62e-05	CcSEcCtD
Bortezomib—Nervous system disorder—Methotrexate—breast cancer	8.21e-06	4.61e-05	CcSEcCtD
Bortezomib—Anaemia—Doxorubicin—breast cancer	8.21e-06	4.61e-05	CcSEcCtD
Bortezomib—Thrombocytopenia—Methotrexate—breast cancer	8.2e-06	4.6e-05	CcSEcCtD
Bortezomib—Myalgia—Epirubicin—breast cancer	8.18e-06	4.59e-05	CcSEcCtD
Bortezomib—Arthralgia—Epirubicin—breast cancer	8.18e-06	4.59e-05	CcSEcCtD
Bortezomib—Chest pain—Epirubicin—breast cancer	8.18e-06	4.59e-05	CcSEcCtD
Bortezomib—Agitation—Doxorubicin—breast cancer	8.17e-06	4.58e-05	CcSEcCtD
Bortezomib—Anxiety—Epirubicin—breast cancer	8.15e-06	4.57e-05	CcSEcCtD
Bortezomib—Nausea—Paclitaxel—breast cancer	8.14e-06	4.57e-05	CcSEcCtD
Bortezomib—Skin disorder—Methotrexate—breast cancer	8.14e-06	4.57e-05	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	8.12e-06	4.56e-05	CcSEcCtD
Bortezomib—Hyperhidrosis—Methotrexate—breast cancer	8.1e-06	4.55e-05	CcSEcCtD
Bortezomib—Discomfort—Epirubicin—breast cancer	8.08e-06	4.53e-05	CcSEcCtD
Bortezomib—Asthenia—Capecitabine—breast cancer	8.07e-06	4.53e-05	CcSEcCtD
Bortezomib—Malaise—Doxorubicin—breast cancer	8.01e-06	4.5e-05	CcSEcCtD
Bortezomib—Vertigo—Doxorubicin—breast cancer	7.98e-06	4.48e-05	CcSEcCtD
Bortezomib—Anorexia—Methotrexate—breast cancer	7.98e-06	4.48e-05	CcSEcCtD
Bortezomib—Syncope—Doxorubicin—breast cancer	7.97e-06	4.47e-05	CcSEcCtD
Bortezomib—Pruritus—Capecitabine—breast cancer	7.96e-06	4.47e-05	CcSEcCtD
Bortezomib—Leukopenia—Doxorubicin—breast cancer	7.95e-06	4.47e-05	CcSEcCtD
Bortezomib—Diarrhoea—Docetaxel—breast cancer	7.95e-06	4.46e-05	CcSEcCtD
Bortezomib—Confusional state—Epirubicin—breast cancer	7.9e-06	4.44e-05	CcSEcCtD
Bortezomib—Palpitations—Doxorubicin—breast cancer	7.85e-06	4.41e-05	CcSEcCtD
Bortezomib—Anaphylactic shock—Epirubicin—breast cancer	7.84e-06	4.4e-05	CcSEcCtD
Bortezomib—Oedema—Epirubicin—breast cancer	7.84e-06	4.4e-05	CcSEcCtD
Bortezomib—Hypotension—Methotrexate—breast cancer	7.83e-06	4.39e-05	CcSEcCtD
Bortezomib—Loss of consciousness—Doxorubicin—breast cancer	7.81e-06	4.38e-05	CcSEcCtD
Bortezomib—Infection—Epirubicin—breast cancer	7.79e-06	4.37e-05	CcSEcCtD
Bortezomib—Cough—Doxorubicin—breast cancer	7.75e-06	4.35e-05	CcSEcCtD
Bortezomib—Shock—Epirubicin—breast cancer	7.71e-06	4.33e-05	CcSEcCtD
Bortezomib—Convulsion—Doxorubicin—breast cancer	7.7e-06	4.32e-05	CcSEcCtD
Bortezomib—Diarrhoea—Capecitabine—breast cancer	7.7e-06	4.32e-05	CcSEcCtD
Bortezomib—Nervous system disorder—Epirubicin—breast cancer	7.69e-06	4.31e-05	CcSEcCtD
Bortezomib—Dizziness—Docetaxel—breast cancer	7.68e-06	4.31e-05	CcSEcCtD
Bortezomib—Thrombocytopenia—Epirubicin—breast cancer	7.67e-06	4.31e-05	CcSEcCtD
Bortezomib—Hypertension—Doxorubicin—breast cancer	7.67e-06	4.31e-05	CcSEcCtD
Bortezomib—Tachycardia—Epirubicin—breast cancer	7.65e-06	4.29e-05	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Methotrexate—breast cancer	7.63e-06	4.28e-05	CcSEcCtD
Bortezomib—Skin disorder—Epirubicin—breast cancer	7.61e-06	4.27e-05	CcSEcCtD
Bortezomib—Hyperhidrosis—Epirubicin—breast cancer	7.58e-06	4.25e-05	CcSEcCtD
Bortezomib—Insomnia—Methotrexate—breast cancer	7.58e-06	4.25e-05	CcSEcCtD
Bortezomib—Arthralgia—Doxorubicin—breast cancer	7.57e-06	4.25e-05	CcSEcCtD
Bortezomib—Myalgia—Doxorubicin—breast cancer	7.57e-06	4.25e-05	CcSEcCtD
Bortezomib—Chest pain—Doxorubicin—breast cancer	7.57e-06	4.25e-05	CcSEcCtD
Bortezomib—Anxiety—Doxorubicin—breast cancer	7.54e-06	4.23e-05	CcSEcCtD
Bortezomib—Paraesthesia—Methotrexate—breast cancer	7.52e-06	4.22e-05	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	7.51e-06	4.22e-05	CcSEcCtD
Bortezomib—Discomfort—Doxorubicin—breast cancer	7.47e-06	4.2e-05	CcSEcCtD
Bortezomib—Anorexia—Epirubicin—breast cancer	7.47e-06	4.19e-05	CcSEcCtD
Bortezomib—Dyspnoea—Methotrexate—breast cancer	7.47e-06	4.19e-05	CcSEcCtD
Bortezomib—Dizziness—Capecitabine—breast cancer	7.44e-06	4.18e-05	CcSEcCtD
Bortezomib—Vomiting—Docetaxel—breast cancer	7.39e-06	4.15e-05	CcSEcCtD
Bortezomib—Dyspepsia—Methotrexate—breast cancer	7.37e-06	4.14e-05	CcSEcCtD
Bortezomib—Rash—Docetaxel—breast cancer	7.33e-06	4.11e-05	CcSEcCtD
Bortezomib—Hypotension—Epirubicin—breast cancer	7.32e-06	4.11e-05	CcSEcCtD
Bortezomib—Dermatitis—Docetaxel—breast cancer	7.32e-06	4.11e-05	CcSEcCtD
Bortezomib—Confusional state—Doxorubicin—breast cancer	7.31e-06	4.1e-05	CcSEcCtD
Bortezomib—Decreased appetite—Methotrexate—breast cancer	7.28e-06	4.09e-05	CcSEcCtD
Bortezomib—Headache—Docetaxel—breast cancer	7.28e-06	4.09e-05	CcSEcCtD
Bortezomib—Anaphylactic shock—Doxorubicin—breast cancer	7.25e-06	4.07e-05	CcSEcCtD
Bortezomib—Oedema—Doxorubicin—breast cancer	7.25e-06	4.07e-05	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Methotrexate—breast cancer	7.23e-06	4.06e-05	CcSEcCtD
Bortezomib—Fatigue—Methotrexate—breast cancer	7.22e-06	4.05e-05	CcSEcCtD
Bortezomib—Infection—Doxorubicin—breast cancer	7.21e-06	4.04e-05	CcSEcCtD
Bortezomib—Pain—Methotrexate—breast cancer	7.16e-06	4.02e-05	CcSEcCtD
Bortezomib—Vomiting—Capecitabine—breast cancer	7.15e-06	4.02e-05	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Epirubicin—breast cancer	7.14e-06	4.01e-05	CcSEcCtD
Bortezomib—Shock—Doxorubicin—breast cancer	7.14e-06	4.01e-05	CcSEcCtD
Bortezomib—Nervous system disorder—Doxorubicin—breast cancer	7.11e-06	3.99e-05	CcSEcCtD
Bortezomib—Thrombocytopenia—Doxorubicin—breast cancer	7.1e-06	3.99e-05	CcSEcCtD
Bortezomib—Rash—Capecitabine—breast cancer	7.09e-06	3.98e-05	CcSEcCtD
Bortezomib—Insomnia—Epirubicin—breast cancer	7.09e-06	3.98e-05	CcSEcCtD
Bortezomib—Dermatitis—Capecitabine—breast cancer	7.09e-06	3.98e-05	CcSEcCtD
Bortezomib—Tachycardia—Doxorubicin—breast cancer	7.08e-06	3.97e-05	CcSEcCtD
Bortezomib—Headache—Capecitabine—breast cancer	7.05e-06	3.96e-05	CcSEcCtD
Bortezomib—Skin disorder—Doxorubicin—breast cancer	7.04e-06	3.95e-05	CcSEcCtD
Bortezomib—Paraesthesia—Epirubicin—breast cancer	7.04e-06	3.95e-05	CcSEcCtD
Bortezomib—Hyperhidrosis—Doxorubicin—breast cancer	7.01e-06	3.94e-05	CcSEcCtD
Bortezomib—Dyspnoea—Epirubicin—breast cancer	6.99e-06	3.92e-05	CcSEcCtD
Bortezomib—Anorexia—Doxorubicin—breast cancer	6.91e-06	3.88e-05	CcSEcCtD
Bortezomib—Nausea—Docetaxel—breast cancer	6.9e-06	3.87e-05	CcSEcCtD
Bortezomib—Feeling abnormal—Methotrexate—breast cancer	6.9e-06	3.87e-05	CcSEcCtD
Bortezomib—Dyspepsia—Epirubicin—breast cancer	6.9e-06	3.87e-05	CcSEcCtD
Bortezomib—Gastrointestinal pain—Methotrexate—breast cancer	6.85e-06	3.84e-05	CcSEcCtD
Bortezomib—Decreased appetite—Epirubicin—breast cancer	6.81e-06	3.82e-05	CcSEcCtD
Bortezomib—Hypotension—Doxorubicin—breast cancer	6.78e-06	3.8e-05	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Epirubicin—breast cancer	6.77e-06	3.8e-05	CcSEcCtD
Bortezomib—Fatigue—Epirubicin—breast cancer	6.76e-06	3.79e-05	CcSEcCtD
Bortezomib—Pain—Epirubicin—breast cancer	6.7e-06	3.76e-05	CcSEcCtD
Bortezomib—Constipation—Epirubicin—breast cancer	6.7e-06	3.76e-05	CcSEcCtD
Bortezomib—Nausea—Capecitabine—breast cancer	6.68e-06	3.75e-05	CcSEcCtD
Bortezomib—Urticaria—Methotrexate—breast cancer	6.65e-06	3.74e-05	CcSEcCtD
Bortezomib—Abdominal pain—Methotrexate—breast cancer	6.62e-06	3.72e-05	CcSEcCtD
Bortezomib—Body temperature increased—Methotrexate—breast cancer	6.62e-06	3.72e-05	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Doxorubicin—breast cancer	6.61e-06	3.71e-05	CcSEcCtD
Bortezomib—Insomnia—Doxorubicin—breast cancer	6.56e-06	3.68e-05	CcSEcCtD
Bortezomib—Paraesthesia—Doxorubicin—breast cancer	6.51e-06	3.66e-05	CcSEcCtD
Bortezomib—Dyspnoea—Doxorubicin—breast cancer	6.47e-06	3.63e-05	CcSEcCtD
Bortezomib—Feeling abnormal—Epirubicin—breast cancer	6.46e-06	3.63e-05	CcSEcCtD
Bortezomib—Gastrointestinal pain—Epirubicin—breast cancer	6.41e-06	3.6e-05	CcSEcCtD
Bortezomib—Dyspepsia—Doxorubicin—breast cancer	6.38e-06	3.58e-05	CcSEcCtD
Bortezomib—Decreased appetite—Doxorubicin—breast cancer	6.3e-06	3.54e-05	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Doxorubicin—breast cancer	6.26e-06	3.51e-05	CcSEcCtD
Bortezomib—Fatigue—Doxorubicin—breast cancer	6.25e-06	3.51e-05	CcSEcCtD
Bortezomib—Urticaria—Epirubicin—breast cancer	6.23e-06	3.5e-05	CcSEcCtD
Bortezomib—Pain—Doxorubicin—breast cancer	6.2e-06	3.48e-05	CcSEcCtD
Bortezomib—Constipation—Doxorubicin—breast cancer	6.2e-06	3.48e-05	CcSEcCtD
Bortezomib—Abdominal pain—Epirubicin—breast cancer	6.2e-06	3.48e-05	CcSEcCtD
Bortezomib—Body temperature increased—Epirubicin—breast cancer	6.2e-06	3.48e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Methotrexate—breast cancer	6.17e-06	3.46e-05	CcSEcCtD
Bortezomib—Asthenia—Methotrexate—breast cancer	6.01e-06	3.37e-05	CcSEcCtD
Bortezomib—Feeling abnormal—Doxorubicin—breast cancer	5.98e-06	3.35e-05	CcSEcCtD
Bortezomib—Gastrointestinal pain—Doxorubicin—breast cancer	5.93e-06	3.33e-05	CcSEcCtD
Bortezomib—Pruritus—Methotrexate—breast cancer	5.93e-06	3.33e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Epirubicin—breast cancer	5.77e-06	3.24e-05	CcSEcCtD
Bortezomib—Urticaria—Doxorubicin—breast cancer	5.76e-06	3.23e-05	CcSEcCtD
Bortezomib—Body temperature increased—Doxorubicin—breast cancer	5.73e-06	3.22e-05	CcSEcCtD
Bortezomib—Abdominal pain—Doxorubicin—breast cancer	5.73e-06	3.22e-05	CcSEcCtD
Bortezomib—Diarrhoea—Methotrexate—breast cancer	5.73e-06	3.22e-05	CcSEcCtD
Bortezomib—Asthenia—Epirubicin—breast cancer	5.62e-06	3.16e-05	CcSEcCtD
Bortezomib—Pruritus—Epirubicin—breast cancer	5.55e-06	3.11e-05	CcSEcCtD
Bortezomib—Dizziness—Methotrexate—breast cancer	5.54e-06	3.11e-05	CcSEcCtD
Bortezomib—Diarrhoea—Epirubicin—breast cancer	5.36e-06	3.01e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Doxorubicin—breast cancer	5.34e-06	3e-05	CcSEcCtD
Bortezomib—Vomiting—Methotrexate—breast cancer	5.33e-06	2.99e-05	CcSEcCtD
Bortezomib—Rash—Methotrexate—breast cancer	5.28e-06	2.96e-05	CcSEcCtD
Bortezomib—Dermatitis—Methotrexate—breast cancer	5.28e-06	2.96e-05	CcSEcCtD
Bortezomib—Headache—Methotrexate—breast cancer	5.25e-06	2.95e-05	CcSEcCtD
Bortezomib—Asthenia—Doxorubicin—breast cancer	5.2e-06	2.92e-05	CcSEcCtD
Bortezomib—Dizziness—Epirubicin—breast cancer	5.18e-06	2.91e-05	CcSEcCtD
Bortezomib—Pruritus—Doxorubicin—breast cancer	5.13e-06	2.88e-05	CcSEcCtD
Bortezomib—Vomiting—Epirubicin—breast cancer	4.98e-06	2.8e-05	CcSEcCtD
Bortezomib—Nausea—Methotrexate—breast cancer	4.98e-06	2.79e-05	CcSEcCtD
Bortezomib—Diarrhoea—Doxorubicin—breast cancer	4.96e-06	2.79e-05	CcSEcCtD
Bortezomib—Rash—Epirubicin—breast cancer	4.94e-06	2.77e-05	CcSEcCtD
Bortezomib—Dermatitis—Epirubicin—breast cancer	4.94e-06	2.77e-05	CcSEcCtD
Bortezomib—Headache—Epirubicin—breast cancer	4.91e-06	2.76e-05	CcSEcCtD
Bortezomib—Dizziness—Doxorubicin—breast cancer	4.8e-06	2.69e-05	CcSEcCtD
Bortezomib—Nausea—Epirubicin—breast cancer	4.66e-06	2.61e-05	CcSEcCtD
Bortezomib—Vomiting—Doxorubicin—breast cancer	4.61e-06	2.59e-05	CcSEcCtD
Bortezomib—Rash—Doxorubicin—breast cancer	4.57e-06	2.57e-05	CcSEcCtD
Bortezomib—Dermatitis—Doxorubicin—breast cancer	4.57e-06	2.56e-05	CcSEcCtD
Bortezomib—Headache—Doxorubicin—breast cancer	4.54e-06	2.55e-05	CcSEcCtD
Bortezomib—Nausea—Doxorubicin—breast cancer	4.31e-06	2.42e-05	CcSEcCtD
Bortezomib—CYP1A2—Metabolism—CYP2D6—breast cancer	9.6e-07	7.24e-06	CbGpPWpGaD
Bortezomib—PSMB1—Disease—AKT1—breast cancer	9.59e-07	7.23e-06	CbGpPWpGaD
Bortezomib—PSMB5—Disease—AKT1—breast cancer	9.59e-07	7.23e-06	CbGpPWpGaD
Bortezomib—PSMB2—Disease—AKT1—breast cancer	9.59e-07	7.23e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTM1—breast cancer	9.57e-07	7.22e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—NCOR1—breast cancer	9.57e-07	7.22e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PLA2G4A—breast cancer	9.57e-07	7.22e-06	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL6—breast cancer	9.56e-07	7.21e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—HSP90AA1—breast cancer	9.55e-07	7.21e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ALB—breast cancer	9.55e-07	7.2e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MYC—breast cancer	9.55e-07	7.2e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TGFB1—breast cancer	9.52e-07	7.18e-06	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL6—breast cancer	9.51e-07	7.17e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EGFR—breast cancer	9.47e-07	7.14e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EGFR—breast cancer	9.47e-07	7.14e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EGFR—breast cancer	9.47e-07	7.14e-06	CbGpPWpGaD
Bortezomib—PSMB8—Disease—AKT1—breast cancer	9.45e-07	7.13e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—breast cancer	9.43e-07	7.11e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NCOA2—breast cancer	9.43e-07	7.11e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—NCOA1—breast cancer	9.38e-07	7.07e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—COMT—breast cancer	9.34e-07	7.04e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EGFR—breast cancer	9.34e-07	7.04e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTP1—breast cancer	9.3e-07	7.01e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—NCOA1—breast cancer	9.29e-07	7.01e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP19A1—breast cancer	9.24e-07	6.97e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—STK11—breast cancer	9.24e-07	6.97e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—MTHFR—breast cancer	9.23e-07	6.96e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—HMOX1—breast cancer	9.17e-07	6.91e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GPX1—breast cancer	9.17e-07	6.91e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP19A1—breast cancer	9.16e-07	6.91e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—STK11—breast cancer	9.16e-07	6.91e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ITPR1—breast cancer	9.15e-07	6.9e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—FASN—breast cancer	9.14e-07	6.89e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—NOS3—breast cancer	9.13e-07	6.89e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—MED12—breast cancer	9.12e-07	6.88e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—DPYD—breast cancer	9.12e-07	6.88e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—BCHE—breast cancer	9.1e-07	6.87e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CYP1A1—breast cancer	9.07e-07	6.84e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ERCC2—breast cancer	9e-07	6.79e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SLC5A5—breast cancer	8.99e-07	6.78e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALDOA—breast cancer	8.98e-07	6.77e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—KRAS—breast cancer	8.95e-07	6.75e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—KRAS—breast cancer	8.95e-07	6.75e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KRAS—breast cancer	8.95e-07	6.75e-06	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—AKT1—breast cancer	8.86e-07	6.68e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—KRAS—breast cancer	8.82e-07	6.65e-06	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—AKT1—breast cancer	8.82e-07	6.65e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ABCB1—breast cancer	8.8e-07	6.64e-06	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—AKT1—breast cancer	8.78e-07	6.62e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NCOA3—breast cancer	8.72e-07	6.57e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SLC2A1—breast cancer	8.68e-07	6.55e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NQO1—breast cancer	8.68e-07	6.55e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SLC2A2—breast cancer	8.65e-07	6.53e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—TYMS—breast cancer	8.64e-07	6.52e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—breast cancer	8.6e-07	6.49e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—COMT—breast cancer	8.59e-07	6.48e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTP1—breast cancer	8.55e-07	6.45e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—NCOR1—breast cancer	8.54e-07	6.44e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PLA2G4A—breast cancer	8.54e-07	6.44e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTM1—breast cancer	8.54e-07	6.44e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—COMT—breast cancer	8.52e-07	6.42e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CAV1—breast cancer	8.51e-07	6.42e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	8.5e-07	6.41e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CPT1A—breast cancer	8.48e-07	6.39e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—MTR—breast cancer	8.48e-07	6.39e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ABCG2—breast cancer	8.48e-07	6.39e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTP1—breast cancer	8.48e-07	6.39e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP3A4—breast cancer	8.47e-07	6.39e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—MTHFR—breast cancer	8.46e-07	6.38e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—HMOX1—breast cancer	8.43e-07	6.36e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CB—breast cancer	8.43e-07	6.36e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	8.43e-07	6.35e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ITPR1—breast cancer	8.41e-07	6.35e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—HMOX1—breast cancer	8.36e-07	6.3e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTGS2—breast cancer	8.35e-07	6.3e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ITPR1—breast cancer	8.34e-07	6.29e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP1B1—breast cancer	8.33e-07	6.28e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HPGDS—breast cancer	8.31e-07	6.27e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HBA1—breast cancer	8.26e-07	6.23e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PIK3CA—breast cancer	8.22e-07	6.2e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PIK3CA—breast cancer	8.22e-07	6.2e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PIK3CA—breast cancer	8.22e-07	6.2e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GPX1—breast cancer	8.18e-07	6.17e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—HSP90AA1—breast cancer	8.17e-07	6.16e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	8.13e-07	6.13e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PIK3CA—breast cancer	8.1e-07	6.11e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CYP1A1—breast cancer	8.1e-07	6.11e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ABCB1—breast cancer	8.09e-07	6.1e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTT1—breast cancer	8.06e-07	6.08e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ACHE—breast cancer	8.06e-07	6.08e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ERCC2—breast cancer	8.03e-07	6.06e-06	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—AKT1—breast cancer	8.03e-07	6.06e-06	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—AKT1—breast cancer	8.03e-07	6.06e-06	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—AKT1—breast cancer	8.03e-07	6.06e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ABCB1—breast cancer	8.02e-07	6.05e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—breast cancer	7.95e-07	6e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—breast cancer	7.95e-07	6e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—breast cancer	7.95e-07	6e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—TYMS—breast cancer	7.95e-07	5.99e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NCOA1—breast cancer	7.94e-07	5.99e-06	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—AKT1—breast cancer	7.92e-07	5.97e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—TYMS—breast cancer	7.88e-07	5.94e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTM1—breast cancer	7.86e-07	5.93e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—NCOR1—breast cancer	7.86e-07	5.93e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PLA2G4A—breast cancer	7.86e-07	5.93e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—breast cancer	7.84e-07	5.91e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—STK11—breast cancer	7.83e-07	5.9e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP19A1—breast cancer	7.83e-07	5.9e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CAV1—breast cancer	7.8e-07	5.88e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PLA2G4A—breast cancer	7.79e-07	5.87e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—NCOR1—breast cancer	7.79e-07	5.87e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTM1—breast cancer	7.79e-07	5.87e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CG—breast cancer	7.75e-07	5.85e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP17A1—breast cancer	7.63e-07	5.76e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HRAS—breast cancer	7.6e-07	5.74e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HRAS—breast cancer	7.6e-07	5.74e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—HRAS—breast cancer	7.6e-07	5.74e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS1—breast cancer	7.56e-07	5.7e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ENO1—breast cancer	7.56e-07	5.7e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—MTHFR—breast cancer	7.55e-07	5.69e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GPX1—breast cancer	7.52e-07	5.67e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HRAS—breast cancer	7.5e-07	5.65e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GPX1—breast cancer	7.46e-07	5.63e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	7.45e-07	5.62e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP1A1—breast cancer	7.45e-07	5.62e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP2D6—breast cancer	7.41e-07	5.59e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ERCC2—breast cancer	7.39e-07	5.57e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP1A1—breast cancer	7.38e-07	5.57e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—breast cancer	7.35e-07	5.54e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ERCC2—breast cancer	7.32e-07	5.52e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTEN—breast cancer	7.28e-07	5.49e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL6—breast cancer	7.28e-07	5.49e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL6—breast cancer	7.28e-07	5.49e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL6—breast cancer	7.28e-07	5.49e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—COMT—breast cancer	7.28e-07	5.49e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NCOA2—breast cancer	7.27e-07	5.49e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTP1—breast cancer	7.24e-07	5.46e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL6—breast cancer	7.18e-07	5.41e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—HMOX1—breast cancer	7.14e-07	5.39e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ITPR1—breast cancer	7.13e-07	5.38e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CG—breast cancer	7.11e-07	5.36e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—FASN—breast cancer	7.06e-07	5.32e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—BCHE—breast cancer	7.03e-07	5.3e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CAV1—breast cancer	6.96e-07	5.25e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—MTHFR—breast cancer	6.94e-07	5.24e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SLC5A5—breast cancer	6.94e-07	5.23e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—MTHFR—breast cancer	6.88e-07	5.19e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ABCB1—breast cancer	6.86e-07	5.17e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CD—breast cancer	6.81e-07	5.14e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—TYMS—breast cancer	6.73e-07	5.08e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ALB—breast cancer	6.73e-07	5.07e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—AKT1—breast cancer	6.71e-07	5.06e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—AKT1—breast cancer	6.71e-07	5.06e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—AKT1—breast cancer	6.71e-07	5.06e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NQO1—breast cancer	6.7e-07	5.05e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SLC2A1—breast cancer	6.7e-07	5.05e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTM1—breast cancer	6.66e-07	5.02e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PLA2G4A—breast cancer	6.66e-07	5.02e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NCOR1—breast cancer	6.66e-07	5.02e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	6.65e-07	5.02e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—AKT1—breast cancer	6.62e-07	4.99e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—NOS3—breast cancer	6.43e-07	4.85e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP1B1—breast cancer	6.43e-07	4.85e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CAV1—breast cancer	6.41e-07	4.83e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GPX1—breast cancer	6.37e-07	4.81e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CAV1—breast cancer	6.35e-07	4.79e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CG—breast cancer	6.34e-07	4.78e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP1A1—breast cancer	6.31e-07	4.76e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HSP90AA1—breast cancer	6.3e-07	4.75e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ERCC2—breast cancer	6.26e-07	4.72e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CD—breast cancer	6.25e-07	4.71e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ALB—breast cancer	6.17e-07	4.65e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NCOA1—breast cancer	6.13e-07	4.62e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	6.07e-07	4.58e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—STK11—breast cancer	6.04e-07	4.56e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP19A1—breast cancer	6.04e-07	4.56e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CB—breast cancer	5.94e-07	4.48e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—NOS3—breast cancer	5.9e-07	4.45e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTGS2—breast cancer	5.89e-07	4.44e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—MTHFR—breast cancer	5.88e-07	4.44e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CG—breast cancer	5.83e-07	4.4e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CG—breast cancer	5.78e-07	4.36e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—COMT—breast cancer	5.62e-07	4.24e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTP1—breast cancer	5.59e-07	4.22e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CD—breast cancer	5.58e-07	4.21e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HMOX1—breast cancer	5.51e-07	4.16e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ALB—breast cancer	5.5e-07	4.15e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ITPR1—breast cancer	5.5e-07	4.15e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CB—breast cancer	5.45e-07	4.11e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CAV1—breast cancer	5.43e-07	4.09e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS2—breast cancer	5.4e-07	4.07e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ABCB1—breast cancer	5.29e-07	3.99e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—NOS3—breast cancer	5.27e-07	3.97e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—TYMS—breast cancer	5.2e-07	3.92e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	5.18e-07	3.91e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CA—breast cancer	5.14e-07	3.88e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PLA2G4A—breast cancer	5.14e-07	3.87e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NCOR1—breast cancer	5.14e-07	3.87e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTM1—breast cancer	5.14e-07	3.87e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTEN—breast cancer	5.13e-07	3.87e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CD—breast cancer	5.13e-07	3.87e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CD—breast cancer	5.08e-07	3.83e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ALB—breast cancer	5.06e-07	3.82e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ALB—breast cancer	5.02e-07	3.79e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CG—breast cancer	4.94e-07	3.73e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GPX1—breast cancer	4.92e-07	3.71e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP1A1—breast cancer	4.87e-07	3.67e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CB—breast cancer	4.86e-07	3.67e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—NOS3—breast cancer	4.84e-07	3.65e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ERCC2—breast cancer	4.83e-07	3.64e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS2—breast cancer	4.82e-07	3.63e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—NOS3—breast cancer	4.8e-07	3.62e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTEN—breast cancer	4.71e-07	3.55e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—MTHFR—breast cancer	4.54e-07	3.42e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CB—breast cancer	4.47e-07	3.37e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CB—breast cancer	4.43e-07	3.34e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS2—breast cancer	4.43e-07	3.34e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS2—breast cancer	4.39e-07	3.31e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CD—breast cancer	4.34e-07	3.28e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ALB—breast cancer	4.29e-07	3.23e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTEN—breast cancer	4.2e-07	3.17e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—AKT1—breast cancer	4.2e-07	3.17e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CAV1—breast cancer	4.19e-07	3.16e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NOS3—breast cancer	4.1e-07	3.09e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTEN—breast cancer	3.86e-07	2.91e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTEN—breast cancer	3.83e-07	2.89e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CG—breast cancer	3.81e-07	2.88e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CB—breast cancer	3.79e-07	2.86e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS2—breast cancer	3.75e-07	2.83e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CA—breast cancer	3.62e-07	2.73e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CD—breast cancer	3.35e-07	2.53e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CA—breast cancer	3.32e-07	2.5e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALB—breast cancer	3.31e-07	2.5e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTEN—breast cancer	3.27e-07	2.47e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NOS3—breast cancer	3.17e-07	2.39e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CA—breast cancer	2.96e-07	2.23e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AKT1—breast cancer	2.96e-07	2.23e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CB—breast cancer	2.92e-07	2.2e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS2—breast cancer	2.9e-07	2.18e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CA—breast cancer	2.73e-07	2.06e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AKT1—breast cancer	2.71e-07	2.05e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CA—breast cancer	2.7e-07	2.04e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTEN—breast cancer	2.53e-07	1.9e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AKT1—breast cancer	2.42e-07	1.83e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CA—breast cancer	2.31e-07	1.74e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AKT1—breast cancer	2.23e-07	1.68e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AKT1—breast cancer	2.21e-07	1.66e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AKT1—breast cancer	1.89e-07	1.42e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CA—breast cancer	1.78e-07	1.34e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AKT1—breast cancer	1.46e-07	1.1e-06	CbGpPWpGaD
